[DOI] [PubMed] [Google Scholar] 81.Sutherland JP, McKinley B, Eckel RH
The nod, which converts a November 2022 accelerated approval, makes Elahere the first and only antibody-drug conjugate (ADC) approved in the U.S. for ovarian cancer, Roopal Thakkar, AbbVies CMO of global therapeutics, said in a statement
ISBN 978-3-510-61411-0
It is frequently utilized in studies examining epithelial signaling, soft-tissue dynamics, and recovery-related pathways, allowing researchers to investigate how peptide-mediated signals influence cellular coordination and system-wide responses
doi: 10.1016/j.bcp.2010.08.010 74 JungSYParkYHKangJHTrautmannMHompeschMKwonSC
[Abstract]2023 Jan:310:136924